Pasithea Therapeutics Corp. (KTTAW) Analyse boursière

Présentation de l'entreprise

Pasithea Therapeutics Corp. operates as a clinical-stage biotechnology entity dedicated to the discovery, research, and development of therapeutic treatments targeting central nervous system (CNS) disorders, RASopathies, and various forms of cancer. Although the specific sector and industry classifications are not explicitly detailed in the available data, the company's operational focus aligns with the biotechnology and pharmaceutical development landscape, where value is derived from pipeline progression rather than current product sales. The organization maintains a highly specialized workforce consisting of five employees, reflecting the typical lean operational structure found in early-stage research and development firms. This minimal headcount, combined with an absence of reported market capitalization and annual revenue figures, indicates that the company is in a pre-commercialization phase where its primary asset is its intellectual property and clinical pipeline rather than existing market share or financial volume.

Santé financière

The company reported a net income loss of $-20,427,684 and an EBITDA loss of $-16,031,099 for the trailing twelve months, while revenue data is not available. The substantial gap between the reported net income and EBITDA losses highlights a significant cost structure burden, likely driven by high research and development expenditures or administrative costs that are not offset by current operational revenue. Free cash flow stands at $-6,473,837, indicating that the company is burning through its capital reserves to fund its development activities, which limits immediate financial flexibility but is common for clinical-stage entities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the absence of commercial revenue streams necessary to generate a positive margin in the traditional sense. On the balance sheet, Pasithea Therapeutics holds $55.16M in cash against zero debt, resulting in a debt-to-equity ratio that is technically unquantifiable due to the lack of equity data but functionally indicates a non-leveraged position. The current ratio is listed at 11.35, a figure suggesting an extremely robust short-term liquidity position relative to current liabilities, though this high ratio must be interpreted within the context of a company with no operating revenue. Return on Equity is reported at -58.4% and Return on Assets at -27.3%, metrics that reveal the company is currently utilizing shareholder and asset bases to generate losses rather than returns, which is a standard characteristic of companies investing heavily in future clinical outcomes rather than current profitability.

Évaluation de la valorisation

Trailing P/E and forward P/E ratios are not applicable for Pasithea Therapeutics Corp., as the company is not yet profitable, meaning there is no denominator to calculate a price-to-earnings multiple. The price-to-book ratio is recorded at 0.00, which indicates that the market capitalization is either zero or negligible compared to the book value, suggesting the stock trades at a discount that reflects its lack of tangible assets or earnings. Similarly, the price-to-sales ratio and EV/EBITDA metrics are not available, as the absence of revenue and positive earnings prevents the calculation of these standard valuation multiples. The stock's 52-week high and low are both listed at $0.01, meaning the current trading price is effectively equal to the 52-week range boundaries with no price discovery movement recorded in this specific dataset. With a beta of 0.25, the stock exhibits low volatility relative to the broader market, implying that its price movements are less sensitive to general market fluctuations, a characteristic often seen in small-cap biotech stocks that trade with limited liquidity.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are not available due to the lack of historical revenue data and the company's status as a loss-making entity. Since the company has not generated sufficient revenue to report positive earnings growth, any hypothetical growth rate would be undefined rather than a percentage figure indicating performance acceleration. Pasithea Therapeutics Corp. does not pay a dividend, as evidenced by a dividend yield and payout ratio that are both not applicable, meaning the company retains all its resources for research and development purposes. Consequently, the company reinvests its remaining cash reserves into its pipeline of central nervous system and cancer treatments rather than distributing income to shareholders, prioritizing long-term clinical milestones over immediate income generation. The overall growth and income profile is defined by a lack of current financial metrics, focusing entirely on the potential future value of its clinical-stage product candidates rather than historical financial performance or income distribution.